vs
Side-by-side financial comparison of Aquestive Therapeutics, Inc. (AQST) and BGSF, INC. (BGSF). Click either name above to swap in a different company.
BGSF, INC. is the larger business by last-quarter revenue ($22.0M vs $13.0M, roughly 1.7× Aquestive Therapeutics, Inc.). BGSF, INC. runs the higher net margin — -5.3% vs -244.8%, a 239.5% gap on every dollar of revenue. On growth, Aquestive Therapeutics, Inc. posted the faster year-over-year revenue change (9.7% vs -9.4%). BGSF, INC. produced more free cash flow last quarter ($1.7M vs $-8.6M). Over the past eight quarters, Aquestive Therapeutics, Inc.'s revenue compounded faster (3.9% CAGR vs -5.3%).
Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for central nervous system disorders. It leverages proprietary drug delivery technologies to create accessible, patient-friendly therapeutic options, serving healthcare providers and patients across North America and European markets, with core offerings addressing unmet needs in neurology and psychiatry.
BGSF Inc. is a leading U.S.-headquartered workforce solutions firm that provides tailored staffing, talent recruitment, and end-to-end workforce management services. It serves core segments including information technology, healthcare, professional administration, light industrial, and creative industries, catering to small, mid-sized and large enterprise clients across North America.
AQST vs BGSF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.0M | $22.0M |
| Net Profit | $-31.9M | $-1.2M |
| Gross Margin | 55.2% | 35.0% |
| Operating Margin | -221.6% | -17.6% |
| Net Margin | -244.8% | -5.3% |
| Revenue YoY | 9.7% | -9.4% |
| Net Profit YoY | -86.8% | -18.2% |
| EPS (diluted) | $-0.26 | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.0M | $22.0M | ||
| Q3 25 | $12.8M | $26.9M | ||
| Q2 25 | $10.0M | $23.5M | ||
| Q1 25 | $8.7M | $20.9M | ||
| Q4 24 | $11.9M | $24.3M | ||
| Q3 24 | $13.5M | $29.8M | ||
| Q2 24 | $20.1M | $25.7M | ||
| Q1 24 | $12.1M | $24.5M |
| Q4 25 | $-31.9M | $-1.2M | ||
| Q3 25 | $-15.4M | $-5.8M | ||
| Q2 25 | $-13.5M | $-3.7M | ||
| Q1 25 | $-22.9M | $-722.0K | ||
| Q4 24 | $-17.1M | $-981.0K | ||
| Q3 24 | $-11.5M | $-804.0K | ||
| Q2 24 | $-2.7M | $-761.0K | ||
| Q1 24 | $-12.8M | $-792.0K |
| Q4 25 | 55.2% | 35.0% | ||
| Q3 25 | 64.8% | 35.9% | ||
| Q2 25 | 54.4% | 35.8% | ||
| Q1 25 | 58.1% | 36.2% | ||
| Q4 24 | 61.9% | 35.9% | ||
| Q3 24 | 67.2% | 35.9% | ||
| Q2 24 | 77.5% | 37.3% | ||
| Q1 24 | 63.6% | 38.1% |
| Q4 25 | -221.6% | -17.6% | ||
| Q3 25 | -89.6% | -3.5% | ||
| Q2 25 | -113.6% | -18.8% | ||
| Q1 25 | -222.1% | 1.6% | ||
| Q4 24 | -114.4% | -15.7% | ||
| Q3 24 | -61.2% | -3.4% | ||
| Q2 24 | 0.3% | -5.7% | ||
| Q1 24 | -74.3% | 1.7% |
| Q4 25 | -244.8% | -5.3% | ||
| Q3 25 | -120.6% | -21.6% | ||
| Q2 25 | -135.4% | -15.9% | ||
| Q1 25 | -263.0% | -3.5% | ||
| Q4 24 | -143.7% | -4.0% | ||
| Q3 24 | -85.0% | -2.7% | ||
| Q2 24 | -13.7% | -3.0% | ||
| Q1 24 | -106.4% | -3.2% |
| Q4 25 | $-0.26 | $-0.12 | ||
| Q3 25 | $-0.14 | $-0.52 | ||
| Q2 25 | $-0.14 | $-0.34 | ||
| Q1 25 | $-0.24 | $-0.06 | ||
| Q4 24 | $-0.18 | — | ||
| Q3 24 | $-0.13 | $-0.07 | ||
| Q2 24 | $-0.03 | $-0.07 | ||
| Q1 24 | $-0.17 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $27.5M | — |
| Stockholders' EquityBook value | $-33.7M | $48.1M |
| Total Assets | $160.4M | $57.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $129.1M | $41.2M | ||
| Q2 25 | $60.5M | $2.8M | ||
| Q1 25 | $68.7M | $2.0M | ||
| Q4 24 | $71.5M | $32.0K | ||
| Q3 24 | $77.9M | $262 | ||
| Q2 24 | $89.9M | $226 | ||
| Q1 24 | $95.2M | $50 |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $45.0M | — | ||
| Q2 25 | $45.0M | — | ||
| Q1 25 | $45.0M | — | ||
| Q4 24 | $32.5M | — | ||
| Q3 24 | $45.0M | — | ||
| Q2 24 | $45.0M | — | ||
| Q1 24 | $45.0M | — |
| Q4 25 | $-33.7M | $48.1M | ||
| Q3 25 | $-4.1M | $50.7M | ||
| Q2 25 | $-72.6M | $78.3M | ||
| Q1 25 | $-60.9M | $81.8M | ||
| Q4 24 | $-60.2M | $82.3M | ||
| Q3 24 | $-45.4M | $82.9M | ||
| Q2 24 | $-35.5M | $83.2M | ||
| Q1 24 | $-36.3M | $83.6M |
| Q4 25 | $160.4M | $57.8M | ||
| Q3 25 | $163.6M | $83.6M | ||
| Q2 25 | $93.7M | $149.7M | ||
| Q1 25 | $102.2M | $152.3M | ||
| Q4 24 | $101.4M | $150.1M | ||
| Q3 24 | $110.0M | $157.3K | ||
| Q2 24 | $117.6M | $159.8K | ||
| Q1 24 | $129.5M | $170.6K |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.5M | $1.7M |
| Free Cash FlowOCF − Capex | $-8.6M | $1.7M |
| FCF MarginFCF / Revenue | -65.7% | 7.6% |
| Capex IntensityCapex / Revenue | 0.7% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-53.0M | $-16.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.5M | $1.7M | ||
| Q3 25 | $-12.6M | $-4.8M | ||
| Q2 25 | $-7.9M | $2.2M | ||
| Q1 25 | $-23.4M | $1.1M | ||
| Q4 24 | $-6.5M | $3.2M | ||
| Q3 24 | $-11.9M | $6.5M | ||
| Q2 24 | $-7.0M | $7.3M | ||
| Q1 24 | $-10.4M | $7.4M |
| Q4 25 | $-8.6M | $1.7M | ||
| Q3 25 | $-12.9M | $-4.9M | ||
| Q2 25 | $-8.0M | $2.1M | ||
| Q1 25 | $-23.5M | $1.0M | ||
| Q4 24 | $-6.5M | $2.5M | ||
| Q3 24 | $-12.0M | $6.5M | ||
| Q2 24 | $-7.0M | $7.3M | ||
| Q1 24 | $-10.4M | $6.9M |
| Q4 25 | -65.7% | 7.6% | ||
| Q3 25 | -100.6% | -18.1% | ||
| Q2 25 | -80.2% | 9.1% | ||
| Q1 25 | -269.9% | 5.0% | ||
| Q4 24 | -54.8% | 10.2% | ||
| Q3 24 | -88.3% | 21.7% | ||
| Q2 24 | -35.0% | 28.5% | ||
| Q1 24 | -86.4% | 28.1% |
| Q4 25 | 0.7% | 0.1% | ||
| Q3 25 | 1.8% | 0.4% | ||
| Q2 25 | 1.1% | 0.0% | ||
| Q1 25 | 1.5% | 0.1% | ||
| Q4 24 | 0.1% | 3.0% | ||
| Q3 24 | 0.6% | 0.0% | ||
| Q2 24 | 0.2% | 0.0% | ||
| Q1 24 | 0.2% | 2.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AQST
Segment breakdown not available.
BGSF
| Contract Field Talent | $21.4M | 97% |
| Other | $595.0K | 3% |
